Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Bachem Holding AG ( (CH:BANB) ).
Bachem Holding AG has secured a CHF 500 million syndicated revolving credit facility with a five-year term, arranged by UBS Switzerland AG and a consortium of domestic and international banks, with an option to increase the facility by an additional CHF 150 million. The new facility will refinance the company’s existing bilateral credit lines, providing a more robust and flexible financing base to support Bachem’s strategic growth initiatives and enhance its operational and financial flexibility as it pursues expansion in peptide and oligonucleotide manufacturing for global pharma and biotech clients.
The most recent analyst rating on (CH:BANB) stock is a Hold with a CHF65.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.
More about Bachem Holding AG
Bachem Holding AG is a Switzerland-based, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. Serving pharmaceutical and biotechnology customers worldwide, it supplies products for research, clinical development and commercial use, and operates internationally with sites in Europe and the U.S. after more than 50 years in the industry.
YTD Price Performance: 13.36%
Average Trading Volume: 136,819
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF5.09B
Find detailed analytics on BANB stock on TipRanks’ Stock Analysis page.